DECOY THERAPEUTICS INC
DCOYNASDAQ🏆 #5149 by market capEarnings Nov 12US Equity
$0.99▼ $0.09 (−8.33%)
Market closed · at closeTrack DCOY
Get earnings, price moves & breaking news on Telegram
24h▼ 8.3%
7d▼ 8.3%
14d▼ 18.9%
30d▼ 53.1%
ytd▼ 87.1%
1y▼ 97.8%
🏦Market Cap
$2M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
48.6%
Healthy
💵FCF Margin
—
⚖️P/S Ratio
11.4x
Elevated
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $0.99 – $0.99
- 52-Week Range
- $0.90 – $47.64
- Volume (shares)
- 820
- Avg Volume (shares)
- —
- Shares Outstanding
- 2.4M
- Next Earnings
- 2026-11-12
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 11.4x
- EPS (TTM)
- $-934.89
- Dividend Yield
- —
- Dilution (1yr)
- +401.3%
DECOY THERAPEUTICS INC
DCOYFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$13M▲ +120.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$5M▲ +6.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
482K▲ +401.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$11M▲ +$8M YoY
StockOtter · stockotter.spaceAbout DECOY THERAPEUTICS INC
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💎Quality★★★★★
⚖️Valuation★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
7 analysts
Strong Buy3
Buy3
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.